This Article Order Full text via Infotrieve Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hruban, R. H. Articles by Offerhaus, G. J. Search for Related Content PubMed PubMed Citation Articles by Hruban, R. H. Articles by Offerhaus, G. J.

American Journal of Pathology, Vol 151, 943-949, Copyright © 1997 by American Society for Investigative Pathology

REGULAR ARTICLES

Can K-ras codon 12 mutations be used to distinguish benign bile duct proliferations from metastases in the liver? A molecular analysis of 101 liver lesions from 93 patients

RH Hruban, PD Sturm, RJ Slebos, RE Wilentz, AR Musler, CJ Yeo, TA Sohn, ML van Velthuysen and GJ Offerhaus
Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, Maryland, USA.

It can be difficult to distinguish benign bile duct proliferations (BDPs) from well-differentiated metastatic peripancreatic adenocarcinomas on histological grounds alone. Most peripancreatic carcinomas harbor activating point mutations in codon 12 of the K-ras oncogene, suggesting that K-ras mutational status may provide a molecular basis for distinguishing BDPs from liver metastases. The ability of tests for mutations in codon 12 of K-ras to make this distinction was examined in a two-part study. In the first part we determined the K-ras mutational status of 56 liver lesions and 48 primary peripancreatic adenocarcinomas obtained from 48 patients. In the second part of this study an additional 45 liver lesions were studied. In the first 48 patients, activating point mutations in codon 12 of K-ras were detected in 28 (61%) of the 46 primary carcinomas, in 8 (100%) of 8 liver metastases, in 2 (6.5%) of 31 BDPs, and in none (0%) of 14 liver granulomas. Three BDPs and two primary carcinomas did not amplify. To further estimate the prevalence of K-ras mutations in BDPs we analyzed an additional series of 45 mostly incidental BDPs for K-ras mutations. Three (6.7%) of these 45 harbored K-ras mutations. These results suggest that K-ras mutations may be useful in distinguishing BDPs from metastases in the liver; however, there is some overlap in the mutational spectra of BDPs and pancreatic carcinomas.

This article has been cited by other articles:

				N T van Heek, S J Clayton, P D J Sturm, J Walker, D J Gouma, L A Noorduyn, G J A Offerhaus, and J C Fox Comparison of the novel quantitative ARMS assay and an enriched PCR-ASO assay for K-ras mutations with conventional cytology on endobiliary brush cytology from 312 consecutive extrahepatic biliary stenoses J. Clin. Pathol., December 1, 2005; 58(12): 1315 - 1320. [Abstract] [Full Text] [PDF]

				W. H. de Vos tot Nederveen Cappel, G. J. A. Offerhaus, M. van Puijenbroek, E. Caspers, N. A. Gruis, F. A. de Snoo, C. B. H. W. Lamers, G. Griffioen, W. Bergman, H. F. A. Vasen, et al. Pancreatic Carcinoma in Carriers of a Specific 19 Base Pair Deletion of CDKN2A/p16 (p16-Leiden) Clin. Cancer Res., September 1, 2003; 9(10): 3598 - 3605. [Abstract] [Full Text] [PDF]

				M Tascilar, B P van Rees, P D J Sturm, G N J Tytgat, R H Hruban, S N Goodman, F M Giardiello, G J A Offerhaus, and A C Tersmette Pancreatic cancer after remote peptic ulcer surgery J. Clin. Pathol., May 1, 2002; 55(5): 340 - 345. [Abstract] [Full Text] [PDF]

				J-C Saurin, M-O Joly-Pharaboz, P Pernas, L Henry, T Ponchon, and J-J Madjar Detection of Ki-ras gene point mutations in bile specimens for the differential diagnosis of malignant and benign biliary strictures Gut, September 1, 2000; 47(3): 357 - 361. [Abstract] [Full Text] [PDF]

				P. D. J. Sturm, E. A. J. Rauws, R. H. Hruban, E. Caspers, T. B. Ramsoekh, K. Huibregtse, L. A. Noorduyn, and G. J. A. Offerhaus Clinical Value of K-ras Codon 12 Analysis and Endobiliary Brush Cytology for the Diagnosis of Malignant Extrahepatic BileDuct Stenosis Clin. Cancer Res., March 1, 1999; 5(3): 629 - 635. [Abstract] [Full Text] [PDF]